- Oops!Something went wrong.Please try again later.
Shares of Epizyme (NASDAQ:EPZM) remained unaffected after the company reported Q3 results.
Earnings per share decreased 37.50% year over year to ($0.55), which beat the estimate of ($0.60).
Revenue of $3,566,000 decreased by 37.60% year over year, which missed the estimate of $5,430,000.
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: Nov 06, 2020
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/7y95p5e9
Recent Stock Performance
Company's 52-week high was at $27.82
52-week low: $11.03
Price action over last quarter: Up 3.99%
Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing & commercializing novel epigenetic medicines. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL), Phase II clinical trial for relapsed or refractory patients with mesothelioma, Phase I dose-escalation and expansion study for children with INI1-negative solid tumors. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias & PRMT5 inhibitor.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.